Alberto
Carmona Bayonas
Asociado Ciencias de la Salud
Hospital Universitario Central de Asturias
Oviedo, EspañaHospital Universitario Central de Asturias -ko ikertzaileekin lankidetzan egindako argitalpenak (105)
2024
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686
-
Physical Activity in Patients with Advanced Cancer: Sociodemographic, Clinical, and Psychological Correlates
Brain Sciences, Vol. 14, Núm. 6
-
Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients
Scientific reports, Vol. 14, Núm. 1, pp. 3188
-
Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial
World Journal of Gastrointestinal Oncology, Vol. 16, Núm. 2, pp. 386-397
2023
-
Can Oncologists Prompt Patient Prognostic Awareness to Enhance Decision-Making? Data From the NEOetic Study
Oncologist, Vol. 28, Núm. 11, pp. 986-995
-
Clinicians’ and Advanced Cancer Patients’ Estimates of Treatment Efficacy and Toxicity in Oncologic Treatment
Healthcare (Switzerland), Vol. 11, Núm. 15
-
Decoding risk: Caravaggio's insights into risk factors for anticoagulation in cancer-associated thrombosis
European Journal of Internal Medicine
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications, Vol. 14, Núm. 1
-
Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 8, pp. 2486-2500
-
Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3492-3500
-
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
PLoS ONE, Vol. 18, Núm. 5 May
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
2022
-
Anxiety and depression in patients with advanced cancer during the COVID-19 pandemic
Supportive Care in Cancer, Vol. 30, Núm. 4, pp. 3363-3370
-
Bayesian interpretation of immunotherapy trials with dynamic treatment effects
European Journal of Cancer, Vol. 161, pp. 79-89
-
Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries
Cancer Investigation, Vol. 40, Núm. 1, pp. 1-13
-
Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence
European Journal of Internal Medicine, Vol. 100, pp. 33-45
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661